Cerus Corporation

Cerus Corporation is a biomedical products company dedicated to enhancing blood transfusion safety through its INTERCEPT Blood System. This platform inactivates a broad range of pathogens, including viruses, bacteria, and parasites, in blood components to reduce the risk of transfusion-transmitted infections. The INTERCEPT system for platelets and plasma holds both CE mark and FDA approval, making it available to blood centers and hospitals globally, including in the United States, Europe, the Commonwealth of Independent States, the Middle East, and select other regions. In the U.S., the INTERCEPT Blood System for Cryoprecipitation produces Pathogen Reduced Cryoprecipitated Fibrinogen Complex, known as INTERCEPT Fibrinogen Complex, a therapeutic for treating bleeding associated with fibrinogen deficiency in settings like trauma, obstetrics, and surgery. The company operates solely in the blood safety segment, supplying these technologies to support safe blood availability for patients. Founded in 1991 and headquartered in Concord, California, Cerus Corporation plays a vital role in transfusion medicine by providing pathogen-protected platelets, plasma, and fibrinogen products.

Sector

Healthcare

Industry

Medical Devices

CEO

Mr. William M. Greenman

Employees

261

Headquarters

Concord, CA, United States

Website

www.cerus.com